BioSpace News Archive

Orexo AB, has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023.

SeaStar Medical Holding Corporation announces that Eric Schlorff, Chief Executive Officer, and Kevin Chung, M.D., Chief Medical Officer, will present a company overview at the Emerging Growth Virtual Conference on Wednesday, March 22, 2023 at 2:15 p.m. Eastern time.

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced that data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2Ar) relapsed/refractory (R/R) acute leukemia and an analysis describing MEN1 mutations observed in the study have been published in the journal Nature.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights.

Werewolf Therapeutics, Inc. today announced the publication of an abstract summarizing an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president, chief financial officer and chief transformation officer, will present and participate in an analyst-led fireside chat at the 2023 virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wed., March 22.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia (AML) harboring a FMS-like tyrosine kinase mutation (FLT3mut+), at the Massachusetts General Hospital in Boston, US.

Nemaura Medical, Inc. announced that it now includes insulin on the list of drugs under the DuoPack Commercial License Agreement with its licensee, MySugarWatch DuoPack Limited.